Scholar Rock (SRRK) Revenue & Revenue Breakdown
Scholar Rock Revenue Highlights
00
Scholar Rock Revenue by Period
Scholar Rock Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $33.19M | 76.41% |
| 2021-12-31 | $18.82M | 22.16% |
| 2020-12-31 | $15.40M | -24.83% |
| 2019-12-31 | $20.49M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $379.00K | - |
Scholar Rock generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Scholar Rock Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $11.66M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $33.19M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $33.19M | 719.78% |
| 2021-12-31 | $4.05M | -25.90% |
| 2021-09-30 | $5.46M | 18.91% |
| 2021-06-30 | $4.59M | -2.40% |
| 2021-03-31 | $4.71M | 37.02% |
| 2020-12-31 | $3.44M | 13.14% |
| 2020-09-30 | $3.04M | -22.13% |
| 2020-06-30 | $3.90M | -22.47% |
| 2020-03-31 | $5.03M | -33.58% |
| 2019-12-31 | $7.57M | 58.63% |
| 2019-09-30 | $4.77M | -5.26% |
| 2019-06-30 | $5.04M | 62.23% |
| 2019-03-31 | $3.11M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Scholar Rock generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Scholar Rock Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $78.50M | $102.40M |
| RLAY | Relay Therapeutics | $25.55M | - |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
| ANAB | AnaptysBio | $17.16M | $30.02M |
| MGTX | MeiraGTx | $14.02M | $10.91M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| IGMS | IGM Biosciences | $2.13M | $516.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| KROS | Keros Therapeutics | $151.00K | $37.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CERE | Cerevel Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| SRRK | Scholar Rock | - | - |